These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 29528698)

  • 41. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Cardiovascular effects of opioid receptor blocker naloxone].
    Osadchiĭ OE; Pokrovskiĭ VM
    Eksp Klin Farmakol; 2001; 64(3):72-5. PubMed ID: 11558446
    [No Abstract]   [Full Text] [Related]  

  • 43. Non-analgesic effects of opioids: mechanisms and potential clinical relevance of opioid-induced immunodepression.
    Sacerdote P; Franchi S; Panerai AE
    Curr Pharm Des; 2012; 18(37):6034-42. PubMed ID: 22747543
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Electrophysiological effects of blocking and stimulating the opioid system in patients with unexplained heart palpitations.
    Oldroyd KG
    Clin Cardiol; 1992 Nov; 15(11):872-3. PubMed ID: 10969635
    [No Abstract]   [Full Text] [Related]  

  • 45. The role of mid-chain hydroxyeicosatetraenoic acids in the pathogenesis of hypertension and cardiac hypertrophy.
    Maayah ZH; El-Kadi AO
    Arch Toxicol; 2016 Jan; 90(1):119-36. PubMed ID: 26525395
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The diverse clinical uses of opioid receptor drugs.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2010 May; 48(5):11-4. PubMed ID: 20415289
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Urocortin 2 in cardiovascular health and disease.
    Adão R; Santos-Ribeiro D; Rademaker MT; Leite-Moreira AF; Brás-Silva C
    Drug Discov Today; 2015 Jul; 20(7):906-14. PubMed ID: 25748088
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Opioid induced hyperalgesia: clinical implications for the pain practitioner.
    Silverman SM
    Pain Physician; 2009; 12(3):679-84. PubMed ID: 19461836
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discriminative Stimulus Properties of Opioid Ligands: Progress and Future Directions.
    Butelman ER; Kreek MJ
    Curr Top Behav Neurosci; 2018; 39():175-192. PubMed ID: 27225498
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Eplerenone: cardiovascular protection.
    Brown NJ
    Circulation; 2003 May; 107(19):2512-8. PubMed ID: 12756192
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical status of methylnaltrexone, a new agent to prevent and manage opioid-induced side effects.
    Yuan CS
    J Support Oncol; 2004; 2(2):111-7; discussion 119-22. PubMed ID: 15328815
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Novel Oral Therapies for Opioid-induced Bowel Dysfunction in Patients with Chronic Noncancer Pain.
    Holder RM; Rhee D
    Pharmacotherapy; 2016 Mar; 36(3):287-99. PubMed ID: 26945548
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of opioid receptor agonists in ischemic preconditioning.
    Dragasis S; Bassiakou E; Iacovidou N; Papadimitriou L; Andreas Steen P; Gulati A; Xanthos T
    Eur J Pharmacol; 2013 Nov; 720(1-3):401-8. PubMed ID: 24120367
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel Beneficial Cardiovascular Effects of Natural Activators of Autophagy.
    Frati G; Vecchione C; Sciarretta S
    Circ Res; 2018 Sep; 123(8):947-949. PubMed ID: 30355035
    [No Abstract]   [Full Text] [Related]  

  • 55. More purinergic receptors deserve attention as therapeutic targets for the treatment of cardiovascular disease.
    Wernly B; Zhou 周稚超 Z
    Am J Physiol Heart Circ Physiol; 2020 Oct; 319(4):H723-H729. PubMed ID: 32822211
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Methylnaltrexone for the treatment of opioid-induced constipation.
    Bader S; Dürk T; Becker G
    Expert Rev Gastroenterol Hepatol; 2013 Jan; 7(1):13-26. PubMed ID: 23265145
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Angiotensin II type 2 receptor (AT2R) in renal and cardiovascular disease.
    Chow BS; Allen TJ
    Clin Sci (Lond); 2016 Aug; 130(15):1307-26. PubMed ID: 27358027
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Duration of opioid receptor blockade determines biotherapeutic response.
    McLaughlin PJ; Zagon IS
    Biochem Pharmacol; 2015 Oct; 97(3):236-46. PubMed ID: 26119823
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intrathecal morphine preconditioning induces cardioprotection via activation of delta, kappa, and mu opioid receptors in rats.
    Li R; Wong GT; Wong TM; Zhang Y; Xia Z; Irwin MG
    Anesth Analg; 2009 Jan; 108(1):23-9. PubMed ID: 19095826
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Opioid drugs and their receptors. A summary of the present state of knowledge.
    Offermeier J; van Rooyen JM
    S Afr Med J; 1984 Aug; 66(8):299-305. PubMed ID: 6147901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.